These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17979736)

  • 21. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
    Till GO; Morganroth ML; Kunkel R; Ward PA
    Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.
    Cheung AK; Parker CJ; Wilcox L
    Clin Exp Immunol; 1989 Nov; 78(2):299-306. PubMed ID: 12412765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation and characterization of transgenic mice expressing cobra venom factor.
    Andrä J; Halter R; Kock MA; Niemann H; Vogel CW; Paul D
    Mol Immunol; 2002 Oct; 39(5-6):357-65. PubMed ID: 12220893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purification of native and recombinant cobra venom factor using thiophilic adsorption chromatography.
    Kölln J; Braren I; Bredehorst R; Spillner E
    Protein Pept Lett; 2007; 14(5):475-80. PubMed ID: 17584174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement depletion with cobra venom factor alleviates acute hepatic injury induced by ischemia‑reperfusion.
    Wang B; Xu H; Li J; Gao HM; Xing YH; Lin Z; Li HJ; Wang YQ; Cao SH
    Mol Med Rep; 2018 Nov; 18(5):4523-4529. PubMed ID: 30221740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The oligosaccharide chains of cobra venom factor are required for complement activation.
    Grier AH; Vogel CW
    Mol Immunol; 1989 Jun; 26(6):563-74. PubMed ID: 2770749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement activation in wasp venom-induced acute kidney injury.
    Cheng R; Xu L; Gong J; Yu F; Lv Y; Yuan H; Hu F
    Ren Fail; 2024 Dec; 46(1):2344658. PubMed ID: 38644359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors in cobra venoms affecting the complement system.
    Vogt W
    Toxicon; 1982; 20(1):299-303. PubMed ID: 7080043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cobra venom factor (CVF)-induced C3 convertase activity in the hemolymph of Galleria mellonella.
    Phipps D; Menger M; Chadwick JS; Aston WP
    Dev Comp Immunol; 1987; 11(1):37-46. PubMed ID: 3647909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury.
    Crawford MH; Grover FL; Kolb WP; McMahan CA; O'Rourke RA; McManus LM; Pinckard RN
    Circulation; 1988 Dec; 78(6):1449-58. PubMed ID: 3191598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolongation of cardiac xenograft survival by depletion of complement.
    Leventhal JR; Dalmasso AP; Cromwell JW; Platt JL; Manivel CJ; Bolman RM; Matas AJ
    Transplantation; 1993 Apr; 55(4):857-65; discussion 865-6. PubMed ID: 8475561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival.
    Candinas D; Lesnikoski BA; Robson SC; Miyatake T; Scesney SM; Marsh HC; Ryan US; Dalmasso AP; Hancock WW; Bach FH
    Transplantation; 1996 Aug; 62(3):336-42. PubMed ID: 8779679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement.
    Smith CA; Vogel CW; Müller-Eberhard HJ
    J Biol Chem; 1982 Sep; 257(17):9879-82. PubMed ID: 6921201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged cardiac allograft survival in mouse model after complement depletion with Yunnan cobra venom factor.
    Wu W; Wang HD; Zhu XX; Lan G; Yang K
    Transplant Proc; 2009 Dec; 41(10):4321-7. PubMed ID: 20005392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja).
    Eggertsen G; Lundwall A; Hellman U; Sjöquist J
    J Immunol; 1983 Oct; 131(4):1920-3. PubMed ID: 6194220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.